This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-19. Anything still debated is marked as such rather than presented as settled.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
=== NIA T32 Training Program for Research Scientists in the Biology of Aging === The NIA T32 Training Program for Research Scientists in the Biology of Aging is one of the nation's premier institutional training programs dedicated to preparing the next generation of leaders in geroscience. Established through support from the National Institute on Aging (NIA), the program provides rigorous multidisciplinary research training for both predoctoral (PhD and MD/PhD) students and postdoctoral fellows pursuing careers in the basic, translational, and clinical biology of aging. For more than three decades, the program has trained investigators who have gone on to become independent scientists, faculty members, and leaders in academia, government, and industry, significantly contributing to advances in aging biology and age-related disease research. The overarching goal of the training program is to develop independent investigators capable of translating discoveries in the fundamental biology of aging into interventions that improve healthspan and reduce the burden of age-associated diseases. Trainees receive individualized, mentor-guided research experiences that integrate molecular, cellular, organismal, and translational approaches to understanding the mechanisms that drive biological aging. The curriculum emphasizes the principles of geroscience—the concept that targeting the biological processes of aging can simultaneously delay or prevent multiple chronic diseases—providing trainees with a broad scientific foundation while encouraging innovative, interdisciplinary research.
1333: Thomasia de Mattio, Italian physician, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1335: Polisena da Troya, licensed Neapolitan surgeon. d. 1366: Jeanne d'Ausshure, French surgeon. fl. 1374: Floreta La-Noga, Aragonese physician. fl. 1376: Virdimura of Catania, Jewish-Sicilian physician. fl. 1380: Bellayne Gallipapa, Zaragoza, Aragonese-Jewish physician. fl. 1384: Dolcich Gallipapa, Lleida, Catalan-Jewish physician. fl. 1384: Juana Sarrovia, Barcelona, Catalan physician. fl. 1387: Na Pla Gallipapa, Zaragoza, Aragonese-Jewish physician. late 13th century: Margherita di Napoli, Napolitan oculist active in Frankfurt-am-Main. fl. 1390: Dorotea Bucca, Italian professor of medicine. 1386–1408: Maesta Antonia, Florentine physician. 14th century: Abella, Italian physician. 14th century: Mercuriade, Italian physician and surgeon. fl. 1400: Antonia Daniello, Florentine-Jewish physician. fl. 13th century: Brunetta de Siena, Italian-Jewish physician. fl. 13th century: Caterina of Florence, Florentine physician. fl. 1411: Peretta Peronne, also called Perretta Petone, French surgeon. fl. 1415: Constance Calenda, Italian surgeon specializing in diseases of the eye. fl. 1438: Jeanne de Cusey, French barber-surgeon. fl. 1460: Marguerite Saluzzi, Napolitan licensed herbalist physician. fl. 1479: Guillemette du Luys, French royal surgeon. d. 1498: Gentile Budrioli (or Gentile Cimieri), Italian astrologer and herbalist. 15th century: Clarice di Durisio, Italian physician. 15th century Francesca, muller de Berenguer Satorra, Catalan physician. c.
=== tif-tik === tifacogin (INN) tifemoxone (INN) tifenamil (INN) tifencillin (INN) tiflamizole (INN) tiflorex (INN) tifluadom (INN) tiflucarbine (INN) tiformin (INN) tifurac (INN) tifuvirtide (INN) Tigan tigapotide (USAN) tigatuzumab (USAN) tigecycline (USAN) tigemonam (INN) tigestol (INN) tigloidine (INN) Tiject-20 Tikosyn
Sources: en.wikipedia.org
== Overdose == A case report of ETH-LAD overdose has been published. The symptoms were rated as moderate to severe and included acute aggression, agitation, unconsciousness, multiple traumatic injuries, metabolic disturbances, and persistent psychosis. Some of the findings were described as unexpected and it was concluded that ETH-LAD may lead to severe toxic effects in overdose in contrast to LSD which is generally well-tolerated. Treatment included benzodiazepines and dexmedetomidine for sedation, antipsychotics for psychotic symptoms, and intensive care for physical complications.
== Bismuth-213 == Bismuth-213 (213Bi) has a half-life of 45.6 minutes and decays mainly by beta emission to polonium-213; with only 2.1% going via alpha emission to thallium-209; however, as the polonium instantly decays by alpha, one alpha particle is emitted per atom. The amounts needed for medical use are always produced through its decay chain (the neptunium series) from either thorium-229 (limited supply due to the long life of that isotope) or actinium-225, which can be produced directly from radium-226, for example by bombardment with bremsstrahlung photons from a linear particle accelerator, knocking out a neutron and through beta decay giving actinium-225. In 1997, an antibody conjugate with 213Bi was used to treat patients with leukemia, and this isotope has otherwise been used in targeted alpha therapy (TAT) to treat a variety of cancers. Bismuth-213 is also produced in the decay of uranium-233, the fuel bred by thorium reactors, but as mentioned this goes through the long-lived thorium-229, so the production rates from each reactor will not be large.
Dulaglutide, sold under the brand name Trulicity, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. This medication is often prescribed for adults and children age 10 and older with type 2 diabetes (citation). It is utilized alongside diet and exercise in order to improve blood sugar. It is also approved in the United States for the reduction of major adverse cardiovascular events such as death, heart attack, or stroke in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is not yet known if it is beneficial, safe, or effective in lowering blood sugar in children under 10 years of age. Trulicity is taken by giving an injection once a week under the skin of your stomach, thigh, or upper arm. The medication is a prescription that comes in the form of a pre-filled single-dose pen in 0.75mg, 1.5mg, 3mg, or 4.5mg per 5mg injection. You are able to take the dosage at any time during the day of administration with/without food eaten. The most common side effects upon administration are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite. Dulaglutide injection is in a class of medications called incretin mimetics, as it is a glucagon-like peptide-1 receptor agonist (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. GLP-1 is a hormone that is involved in normalizing the level of glucose in blood (glycemia). It works by aiding the pancreas to release the correct amount of insulin when blood sugar levels are high.
==== History ==== It was founded in March 1979 as part of the People's Liberation Army Basic Engineering Corps. It was under the joint dual command of the Basic Engineering Corps and the Ministry of Metallurgical Industry. It consisted of 7 regiment level battalions and 12 geological teams. The Gold Corps was handed to the PAP in January 1985. After 1985, it went under the dual control of the Ministry of Metallurgical Industry and Ministry of Public Security. Its role in this time was to do geological surveys for gold mining. After February 1999, it went under the dual control of the People's Armed Police and the State Economic and Trade Commission. Its official duties were: finding gold deposits, providing security and law enforcement to gold mines, mining gold and preventing conflict near gold mines. By 2011, the gold corps had mined 1800 tonnes of gold. The same year in December, its official role switched again to geological surveying and metal analysis along with disaster relief to geological related incidents and law enforcement. In 2016, its role was switched yet again to focus primarily on military geology related work in the Deepening National Defense and Military Reform. In 2018, the Gold Corps was disbanded and its personnel were handed to the Ministry of Natural Resources, the China Geological Survey and the China National Gold Group Corporation.
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.